Baird Financial Group Inc. Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Baird Financial Group Inc. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) by 5.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 70,688 shares of the biopharmaceutical company’s stock after acquiring an additional 3,666 shares during the quarter. Baird Financial Group Inc. owned approximately 0.05% of Halozyme Therapeutics worth $3,111,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. TownSquare Capital LLC grew its stake in shares of Halozyme Therapeutics by 137.8% during the 1st quarter. TownSquare Capital LLC now owns 11,922 shares of the biopharmaceutical company’s stock worth $475,000 after acquiring an additional 6,909 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Halozyme Therapeutics by 17.7% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,791 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 1,020 shares during the period. Mutual of America Capital Management LLC grew its stake in shares of Halozyme Therapeutics by 1.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 128,384 shares of the biopharmaceutical company’s stock worth $5,120,000 after acquiring an additional 2,451 shares during the period. Verdence Capital Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 1.8% in the 1st quarter. Verdence Capital Advisors LLC now owns 14,021 shares of the biopharmaceutical company’s stock valued at $559,000 after acquiring an additional 251 shares in the last quarter. Finally, Torray LLC raised its holdings in shares of Halozyme Therapeutics by 5.5% during the 1st quarter. Torray LLC now owns 37,820 shares of the biopharmaceutical company’s stock valued at $1,508,000 after buying an additional 1,970 shares in the last quarter. Institutional investors own 91.72% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $53.91 on Tuesday. The firm has a market capitalization of $7.29 billion, a price-to-earnings ratio of 36.18, a price-to-earnings-growth ratio of 1.00 and a beta of 1.22. The company has a debt-to-equity ratio of 3.91, a current ratio of 2.72 and a quick ratio of 2.23. The business has a fifty day moving average of $43.68 and a 200 day moving average of $44.39. Halozyme Therapeutics, Inc. has a 1 year low of $31.36 and a 1 year high of $54.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HALO shares. SVB Leerink lifted their price target on Halozyme Therapeutics from $52.00 to $62.00 and gave the stock an “outperform” rating in a research note on Monday. Morgan Stanley assumed coverage on Halozyme Therapeutics in a research report on Friday, September 9th. They set an “overweight” rating and a $50.00 price target on the stock. JMP Securities boosted their price target on Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 9th. Finally, StockNews.com started coverage on Halozyme Therapeutics in a research report on Wednesday, October 12th. They set a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $54.57.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.